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Abstract: Rapid correction of severe hyponatremia carries the risk of
osmotic demyelination. Two recently introduced methods of correction
of hyponatremia have diametrically opposite effects on aquaresis.
Inhibitors of vasopressin V2 receptor (vaptans) lead to the production
of dilute urine, whereas infusion of desmopressin causes urinary
concentration. Identiﬁcation of the category of hyponatremia that will
beneﬁt from one or the other treatment is critical. In general, vaptans are
effective in hyponatremias presenting with concentrated urine and, with
the exception of hypovolemic hyponatremia, can be used as their
primary treatment. Desmopressin is effective in hyponatremias present-
ing with dilute urine or developing urinary dilution after saline infusion.
In this setting, desmopressin infusion helps prevent overcorrection of
the hyponatremia. Monitoring of the changes in serum sodium
concentration as a guide to treatment changes is imperative regardless
of the initial treatment of severe hyponatremia.
Key Indexing Terms: Hyponatremia; Vaptans; Desmopressin. [Am J
Med Sci 2014;348(5):432–439.]
H yponatremia is considered severe when serum sodium con-centration ([Na]s) is ,125 mmol/L1 and/or when hyper-
tonic or isotonic saline is infused to correct severe neurological
manifestations or symptomatic hypovolemia.2 In severe cases
of hyponatremia, the rate of correction of [Na]s is critical for
prevention of either prolonged brain edema or osmotic demy-
elination.2 The current standard is a controlled rate of rise in
[Na]s. Although there is some debate about how rapid the initial
increase in [Na]s should be in severe hyponatremia,
3,4 there is
strong evidence that the incidence of osmotic demyelination in-
creases sharply if the correction exceeds 20 mEq/L in the ﬁrst 24
hours.5 Based on these observations, most experts recommend
slower rates of correction.3–6 Recent guidelines from an expert
panel recommend a minimum rate of correction of [Na]s by 4 to
8 mEq/L per day, and a goal of 4 to 6 mEq/L per day if the risk
of osmotic demyelination syndrome is high.7 The expert panel
set also upper limits in the rate of correction. [Na]s should not rise
by more than 8 mEq/L in any 24-hour period if the risk of
osmotic myelinolysis is high and by no more than 10 to 12
mEq/L in any 24-hour period or 18 mEq/L in any 48-hour period
if the risk of osmotic myelinolysis syndrome is not high.7
Achieving the desired rate of correction of [Na]s is a difﬁ-
cult task. In a recent report, the rise in [Na]s in the ﬁrst 24 hours
of treatment exceeded 12 mEq/L in 11% of the subjects admitted
with severe hyponatremia.8 Saline infusion carries special risks of
overcorrection of hyponatremia. The volume of infused saline is
calculated by formulas that take into account the starting and
target [Na]s values, the concentration of sodium in the infusate
and the volume of body water before the start of saline infu-
sion.2,9 Lack of precision, or inaccuracy, of the clinical estimates
of body water entered in the formulas used to calculate the vol-
ume of infused saline required for a speciﬁc rise in [Na]s are
important sources of error in the predictive formulas.2,10
The major source of error during treatment of hypona-
tremia with saline infusion, however, is not accounted for in the
predictive formulas. The source of this error is the volume and
the concentrations of sodium and potassium of the urine during
the treatment period.2 Two recently proposed strategies
addressed speciﬁcally the effect of urine volume and composi-
tion on [Na]s during treatment of severe hyponatremia. These
strategies, which include use of V2 vasopressin receptor inhib-
itors (vaptans) and infusion of desmopressin along with saline,
have diametrically opposite effects on urinary free water excre-
tion. Vaptans increase water loss in the urine (aquaresis) with-
out changing urinary excretion of sodium or potassium; in
contrast, desmopressin promotes water reabsorption in the
collecting ducts, thereby limiting urinary water loss.
It is therefore imperative to analyze the advantages, risks,
indications and contraindications of these 2 treatments for the
various categories of hyponatremia. The recent guidelines
address some of the uses of vaptans and desmopressin in
hyponatremia.7 The purpose of this report was to provide a ratio-
nale, based on the pathogenetic mechanism of each episode of
severe hyponatremia, for choosing vaptans or desmopressin
plus saline as the method of treatment of severe hyponatremia.
We do not address alternative methods (eg, restriction of ﬂuid
intake, administration of other than vaptan medications block-
ing the effect of vasopressin on the urinary concentrating mech-
anism, urea infusion), all of which may have a role in the
management of severe hyponatremia in particular individuals.
RELATIONSHIP BETWEEN URINE COMPOSITION,
URINE FLOW RATE AND CORRECTION OF [Na]s
As we have previously discussed,2 the changes in [Na]s
can be predicted based on various clinical parameters, including
initial body water volume, urine ﬂow rate and electrolyte com-
position, infusate volume and composition as well as dietary
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ingestion and extrarenal salt and water losses. If we ignore
extrarenal losses, the ﬁnal serum sodium concentration after
infusion of saline ([Na]Fin) is predicted by the equation:
where TBWIni is total body water before the infusion, [Na]Ini is
the initial serum sodium concentration, 1.11 is an empiric cor-
rection term proposed by Edelman et al.11 VInf is the volume of
the infusate, [Na]Inf is the sodium concentration in the infusate,
VUrine is the volume of urine and [Na]Urine and [K]Urine are the
concentrations of sodium and potassium in the urine,
respectively.
Using this formula and assuming starting points attribut-
able to a 70-kg man with a serum sodium of 125 mEq/L, we
performed simulations shown in Figure 1. Reviewing these
ﬁgures, it seems very clear that infusion of substantial amounts
of hypertonic saline would be associated with very high rates of
rise in [Na]s unless the urine remained very concentrated. Ergo,
it would be predicted that the combination of vaptan therapy,
which would cause the elaboration of dilute urine, and hypertonic
saline would likely result in too-rapid rates of correction. Vaptans
or desmopressin are indicated in certain categories of hyponatre-
mia and are contraindicated or ineffective in other categories.
CATEGORIES OF HYPONATREMIA
One large group of hyponatremias is characterized by
high serum vasopressin levels and urine osmolality levels that
½NaFin5
TBWIni3 ½NaIniþ1:113VInf 3 ½NaInf 2VUrine3
½NaUrineþ½KUrine

TBWIni þ   VInf 2   VUrine ;
FIGURE 1. Simulations of the response of [Na]s depending on urine flow and electrolyte content as well as infusate composition and
volume. We began with a 70-kg man (42 L TBWIni) and a [Na]Ini of 125 mEq/L. Simulations are shown in 4 circumstances. Top left panel:
no infusate. Top right panel: 2 L of 5% dextrose in water. Bottom left panel: 2 L of 0.9% saline. Bottom right panel: 2 L of 3% saline.
Urine volume and electrolyte content were allowed to range in the x and y axes between 0 and 10 L and 25 and 300 mEq/L,
respectively. We present simulations as if these occurred after 24 hours and color-coded rates of correction exceeding 20 mEq/L per 24
hours as red with lesser rates of correction having hues moving toward the blue end of the color spectrum.
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are higher than the levels that should normally accompany low
[Na]s levels.
6,8,10,12 High levels of serum vasopressin are the
main cause of the inability to excrete water in this group, which
consists of 3 categories, hypovolemic, euvolemic and hyper-
volemic hyponatremia.7,12
Characterization of volume status in hyponatremic
patients with high levels of serum vasopressin is critical but
encounters serious difﬁculties. Historical evidence, clinical
examination and certain laboratory ﬁndings have traditionally
been the cornerstone of this classiﬁcation.2,7,9,10,12–14 Hypovole-
mic hyponatremia is characterized by history suggesting loss of
volume through the gastrointestinal tract, the kidneys or the
skin, clinical ﬁndings (recent weight loss, orthostatic hypoten-
sion, orthostatic tachycardia, absence of edema) and low
sodium concentration in the urine except when sodium losses
occur through the urine.7,12,13 Euvolemic hyponatremia is char-
acterized by the absence of historical or clinical ﬁndings of
volume deﬁcit and, usually, by relatively high urine sodium
concentration and low serum uric acid level.7,12,13 Hypervole-
mic hyponatremia is characterized by the presence of a disease
causing sodium retention, absence of clinical signs of volume
deﬁcit, signiﬁcant edema ($0.5 cm of pressure-induced edema)
and low urine sodium concentration.7,12,13
The sensitivity and speciﬁcity of clinical criteria in
differentiating between hypovolemic and euvolemic hypona-
tremia are poor.14 Urine sodium concentration is low in hypo-
volemic hyponatremia except in patients with renal losses of
sodium caused by disease or diuretics. Whereas, urine sodium
is high in most patients with euvolemic hyponatremia except
those who experience sodium losses in addition to the primary
condition causing euvolemic hyponatremia.7,14 Serum levels of
norepinephrine and renin, which are high in hypovolemic hy-
ponatremia and low in euvolemic hyponatremia,14 provide bet-
ter discrimination between the 2 states. If doubts persist, careful
infusion of saline in relatively small volumes and monitoring of
urinary water and sodium excretion and of [Na]s may provide
useful information about the category of hyponatremia.2,7,14 The
characterization of volume status in patients with severe hypo-
natremia may beneﬁt from application of the specialized non-
invasive and invasive techniques that are now available for
assessment of intravascular volume in critically ill patients.15
However, we did not ﬁnd any studies that investigated these
techniques in hyponatremia.
The second group of hyponatremias is characterized by
low serum vasopressin levels and typically low urine osmolal-
ity. Mechanisms other than vasopressin excess are primarily
responsible for the water retention in this heterogeneous group,
but vasopressin action may play a secondary role. This group
includes hyponatremia in chronic renal failure,16 psychiatric
disorders,17 potomania,18 low solute load excreted in the urine19
and the sick cell syndrome.20 Resetting of the osmostat may
present with high or low urine osmolality (see below). It will be
classiﬁed in this report in the category of hyponatremia second-
ary to high vasopressin level because patients with resetting of
the osmostat have high vasopressin levels and high urine osmo-
lality when they have hyponatremia.
INDICATIONS AND CONTRAINDICATIONS OF
VAPTANS AND DESMOPRESSIN WITH
SALINE FOR EACH CATEGORY OF
SEVERE HYPONATREMIA
Several reports have analyzed the indications and contra-
indications of vaptan use in hyponatremia.7,21–23 Desmopressin
infusion added to the infusion of hypertonic saline, the volume
of which was calculated by the Adrogué-Madias formula,9
achieved the desired rise in [Na]s in 25 of 25 patients with
severe hyponatremia.24 Overcorrection was not noted. The
treatment with desmopressin infusion was provided to all the
patients, regardless of the category of hyponatremia.24 Table 1
provides synoptic answers to the question whether vaptans and
desmopressin are effective and safe initial treatments in each
category of severe hyponatremia. The remaining text of this
section provides the rationale for the statements in Table 1.
Hyponatremias Resulting Primarily From High
Vasopressin Levels
Inhibition of vasopressin action by vaptans will cause
aquaresis and increases in [Na]s in every category of hypona-
tremia in this group, whereas desmopressin, which is infused to
prevent aquaresis and rapid increases in [Na]s, may be consid-
ered as ineffective given the known fact that increases in serum
vasopressin levels above the level that cause maximal urine
concentration physiologically (5 to 6 pg/mL) have no further
effects on urine osmolality.25 However, there are differences
between the 3 categories of hyponatremia in the indications
and risks of these treatments. Each category is analyzed below.
Hypovolemic Hyponatremia
In this category of hyponatremia, regardless of the
mechanism of hypovolemia, vasopressin secretion is sustained
by hypovolemia. Repletion of the extracellular volume by
infusion of saline corrects the hypovolemia and removes the
volume stimulus for vasopressin release in the circulation.
Vasopressin release is then under the inﬂuence of osmolality,
which is low. Thus, serum vasopressin levels become very low,
resulting in profound aquaresis. Vaptans are unnecessary in this
setting because production of dilute urine will inevitably follow
volume repletion. In fact, vaptan use to treat severe hypona-
tremia is actually dangerous. Aquaresis preceding the correction
of the volume deﬁcit will aggravate this deﬁcit and will also
result in overcorrection of hyponatremia. Reversal of hypovo-
lemia with hypertonic or isotonic saline infusion alone carries
also the risk of overcorrection of hyponatremia because it will
be followed by aquaresis and a rise in [Na]s exceeding that
calculated using the predictive formulas.2 Maintenance of urine
volume at the lowest rate that will allow solute excretion
enhances the accuracy of the formulas that calculate the volume
of infused saline and prevents overcorrection of the hyponatre-
mia.2,6,24 Consequently, hypovolemic hyponatremia constitutes
a prime indication for infusion of desmopressin along with
saline.
Euvolemic Hyponatremias
This category consists of hyponatremias occurring in
endocrine disorders, including the syndrome of inappropriate
vasopressin secretion (SIADH), profound hypothyroidism and
Addison’s disease. SIADH can develop in certain disease states
or can complicate the use of certain drugs.26 Vaptans are effec-
tive in correcting hyponatremia in this syndrome27 and can be
used as initial treatment. Aquaresis resulting from the use of
vaptans, however, is associated with the risk of overcorrection
of hyponatremia. Monitoring of [Na]s and urine output is imper-
ative in this setting. Infusion of hypertonic saline is the pre-
ferred initial step in the treatment of hyponatremia with
profound neurological manifestations.22 Although not danger-
ous, desmopressin infusion in the setting of persistently ele-
vated urine osmolality should be considered ineffective.
The nephrogenic syndrome of inappropriate diuresis is
characterized by severe hyponatremia occurring early in life,
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undetectable (very low) serum vasopressin levels and urine with
high osmolality. This syndrome is caused by a missense
mutation in the gene of the sex-linked V2 receptor in the
basolateral membrane of the principal cells of the collecting
ducts.28 Whether there is any place for vaptans in the treatment
of hyponatremia in patients with this syndrome is not known
currently. Like in SIADH, desmopressin should be ineffective
in this syndrome in which the high urine osmolality will not
decrease during saline infusion.
Euvolemic hyponatremia is encountered in patients with
severe hypothyroidism. The proper treatment for this condition
is thyroid replacement, which corrects the hyponatremia.
Because a vasopressin-mediated component is part of the
inability to excrete water loads in this syndrome,29 it is expected
that vaptans will be effective in correcting hyponatremia. How-
ever, information on the effectiveness of vaptans in this syn-
drome is lacking. Desmopressin and saline infusion may have
a place in the early treatment of severe hyponatremia if thyroid
hormone replacement promptly reverses the urinary diluting
defect of hypothyroidism.
Secondary adrenal insufﬁciency is the third hormonal
deﬁcit leading to euvolemic hyponatremia. Glucocorticoids
facilitate water excretion by the kidneys. Glucocorticoid deﬁcit
is associated with a vasopressin-mediated inability to excrete
water loads that responds to vaptans.30 However, the primary
treatment for this type of hyponatremia is glucocorticoid
replacement. It is possible that desmopressin added to saline
infusion may be useful in the treatment of severe hyponatremia
if concomitant glucocorticoid administration causes an early
reversal of the diluting defect. The hyponatremia of primary
adrenal insufﬁciency with combined glucocorticoid and mineral-
ocorticoid deﬁcits has an important element of volume depletion.
Desmopressin infusion has a role in the simultaneous correction
of hyponatremia and volume defect by infusion of saline.
The concept of resetting of the osmostat has been applied
to patients presenting with hyponatremia31 or hypernatremia32
who on formal testing of urinary dilution by water loading and
concentration by water deprivation behave as if they have
shifted their normal [Na]s downward or upward, respectively.
The diagnosis of this syndrome requires exclusion of other
types of hyponatremia. Resetting of the osmostat is usually seen
in patients with chronic illness and can be combined with other
mechanisms of water retention, such as low solute clearance.33
Measurement of urine osmolality and sodium concentration at
presentation with hyponatremia should guide the choice of ini-
tial treatment. Hyponatremia resulting from resetting of the
TABLE 1. Vaptans and desmopressin in the treatment of severe hyponatremia (effectiveness, risks, indications
and contraindications).
Category of hyponatremia Vaptans Desmopressin
A. With high urine osmolality
Hypovolemic Effective Effectivec
Very high riskab Low risk
Contraindicated Highly indicated
Euvolemic Effective Ineffective
High riskb Low risk
Use with caution Not indicated
Resetting of the osmostat Effective in some cases Effective in some cases
High riskb Low risk
Unknown usefulness Indicated if hypovolemia is also present
Hypervolemic Effective Ineffective
High riskb Low risk
Use with caution Not indicated
A. With typically low urine osmolality
Chronic renal failure Limited effectiveness Limited effectiveness
Low risk Low risk
Questionable usefulness Questionable usefulness
Psychiatric disorders Limited effectiveness Effective
High riskb Low risk
Not indicated Indicated
Beer potomania Limited effectiveness Effective
High riskb Low risk
Not indicated Indicated
Low urinary solute load Ineffective Effective
High riskb Low risk
Not indicated Indicated
Sick cell syndrome Unknown effectiveness Unknown effectiveness
Unknown risks Unknown risks
Unknown usefulness Unknown usefulness
a Risk of worsening hypovolemia.
b Risk of overcorrection of hyponatremia.
c Effective after correction of hypovolemia and removal of the volume stimulus for vasopressin release.
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osmostat should respond to vaptans. However, early use of
vaptans should be avoided. Desmopressin infusion is indicated
if a component of hypovolemia or of low solute availability is
suspected. In euvolemic hyponatremia treated with hypertonic
saline, infusion of large loop diuretics promotes urinary water
losses and can be used instead of vaptans. Frequent monitoring
of the serum sodium concentration is imperative in this setting.
Hypervolemic Hyponatremias
This category of hyponatremias is characterized by
conditions leading to progressive renal salt retention because
of low effective intravascular volume in the absence of sodium
salt deﬁcit. Congestive heart failure, hepatic cirrhosis and the
nephrotic syndrome are conditions that precipitate hypervole-
mic hyponatremia.9 In these conditions, water excretion by the
kidneys is impaired by changes in renal hemodynamics, result-
ing in a low glomerular ﬁltration rate, increased proximal frac-
tional reabsorption values and by high serum levels of
vasopressin released in the circulation by volume stimuli.34–36
The ﬁndings of high urine osmolality and low urine
sodium concentration are indistinguishable between hyper-
volemic hyponatremia and hypovolemic hyponatremia of
extrarenal origin.12 The characteristic difference between these
2 categories of hyponatremia is that saline infusion corrects the
volume deﬁcit and leads to aquaresis in hypovolemic hypona-
tremia but has no effect on the urinary defect in water excretion
and aggravates the volume excess in hypervolemic hyponatre-
mia. This difference guides the choice of treatment for hypona-
tremia. Vaptans are effective in all types of hypervolemic
hyponatremias.37 Tolvaptan should not be used in patients with
hepatic cirrhosis because of diminished effectiveness and a risk
of hepatotoxicity.38 Vaptan use in patients with congestive heart
failure and severe hyponatremia obviates the infusion of saline,
which aggravates the heart failure, but should be accompanied
by measurement of [Na]s every 3 hours to prevent overcorrec-
tion.21 Hypertonic saline should be the initial treatment of hy-
pervolemic hyponatremia with profound neurological
manifestations. Concomitant infusion of loop diuretics facili-
tates water diuresis but, like the vaptan use, should be accom-
panied by frequent measurements of [Na]s. Desmopressin
should be ineffective in a setting of persistently high serum
vasopressin levels and high urine osmolalities.
Hyponatremias Resulting Primarily From
Mechanisms Other Than Vasopressin Release
Hyponatremia of Chronic Renal Failure
Hyponatremia in chronic renal failure is typically
associated with hypervolemia and is often classiﬁed as hyper-
volemic hyponatremia. However, the mechanism of hypona-
tremia differs between chronic renal failure and the conditions
listed in this report under hypervolemic hyponatremia. These
conditions have high serum vasopressin levels and high
osmolality values in the urine. The ability of the kidneys to
produce urine with very low osmolality is preserved in chronic
renal failure.39 In this syndrome, water loading leads to forma-
tion of dilute urine.39 Hyponatremia develops in this setting
because the volume of water that the kidneys are capable to
excrete is too low and can be less than even usual volumes of
ingested water. Loop diuretics may increase water diuresis in
hyponatremic patients with substantial residual renal function.
In contrast to urinary dilution, urine concentration is
impaired in chronic renal failure. The concentrating defect is
resistant to vasopressin infusion.40 Low levels of both the V2
receptor41 and aquaporin-242 have been found in renal failure.
However, experimental animals with renal failure responded to
water restriction with a weak increase in aquaporin-2, a decrease
in urine volume and an increase in urine osmolality.43 Vaptan
administration to patients with severe chronic renal failure and
congestive heart failure increased urine volume and modestly
decreased urine osmolality.44 Thus, vaptans may have a role in
the management of hyponatremia of chronic renal failure. Des-
mopressin infusion will not be needed because of the limited
ability of the kidneys to excrete free water.
Hyponatremia of Psychiatric Disorders
Several categories of drugs used to treat psychiatric
disorders can cause SIADH.23 In addition, primary polydipsia
with hyponatremia is encountered in large numbers of patients
with various psychiatric diagnoses. Most patients with primary
polydipsia have a dilute urine.45 In a number of patients, how-
ever, serum vasopressin was not suppressed adequately.46
Because the urine is not maximally diluted, hyponatremia in
these patients may respond to vaptans.47 However, the main
issue with the treatment of hyponatremia in the setting of exces-
sive ﬂuid intake is that cessation of water intake, which is the
primary treatment, may lead to an inappropriately rapid rise in
[Na]s because of a large volume of dilute urine. Desmopressin
infusion is indicated, but with a note of caution. Impaired abun-
dance of aquaporin-2 protein in this syndrome48 may limit the
effectiveness of desmopressin.
Hyponatremia in Beer Potomania
Excessive ﬂuid intake without any other abnormalities
leads to a characteristic picture of very low to undetectable
serum vasopressin concentration and a dilute urine, with an
osmolality less than 100 mOsm/kg. However, beer drinkers
developing hyponatremia exhibit a variety of biochemical
proﬁles. Speciﬁcally, urine osmolality is .100 mOsm/kg in
several subjects,49,50 whereas urine sodium concentration may
be ,20 mmol/L suggesting hypovolemia, .40 mmol/L sug-
gesting SIADH, reset osmostat or salt wasting and between 20
and 40 mmol/L.49 In this last category, a large rise in [Na]s after
infusion of a test volume of isotonic saline suggests the pres-
ence of hypovolemia.2,49 Low solute intake may contribute to
the inability to excrete the ingested loads of ﬂuid.50 The use of
vaptans may assist in the elucidation of the mechanism of hy-
ponatremia in patients with beer potomania51 but is associated
with a risk of overcorrection of hyponatremia similar to the risk
in hypovolemic hyponatremia. Saline infusion also carries a risk
of overcorrection of hyponatremia, particularly in patients with
hypovolemia.52 The indication for desmopressin infusion in this
setting is strong.
Hyponatremia in Patients With Low Urinary Solute Load
These patients present with dilute urine.19 However, their
ability to excrete water loads is severely limited even when their
urine osmolality is at the lowest attainable level.52 Vaptans
should have no effect on water excretion when urine dilution
is maximal. Solute administration, in the form of saline infu-
sion, rapidly increases free water excretion. Desmopressin infu-
sion, along with saline, hypertonic or isotonic, is indicated in
the initial phase of treatment of severe hyponatremia in this
syndrome.
Hyponatremia in Patients With Sick Cells
The concept of sick cells refers to abnormalities in the
function of transport processes of the cell membranes in
patients with severe illnesses, with exit of low-molecular-
weight organic solutes and water into the extracellular
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compartment.53 The characteristic biochemical picture is one of
hyponatremia, normal serum osmolality and a large osmol gap,
which is the difference between measured serum osmolality and
osmolality calculated as the sum of the osmotic equivalents of
serum sodium, glucose and urea.54 The concept of sick cell as
a cause of hyponatremia has been disputed.55 Even if this syndrome
causes hyponatremia, the changes in cell volume should be oppo-
site in the sick cell syndrome, in which cells lose water, and other
hyponatremias in which cells are swollen. The role of vaptans or
desmopressin in the management of this syndrome is unclear.
Figure 2 shows a ﬂow chart of treatment of hyponatre-
mias with a focus on the use of vaptans or desmopressin.
CONCLUSIONS
The use of vaptans for initial treatment of severe
hyponatremia is associated with serious risks and is ineffective
in certain categories of hyponatremia. The risks of desmopres-
sin infusion are not signiﬁcant. However, this compound will be
ineffective in hyponatremia with persistently elevated urine
osmolality. Cost and side effects of each treatment should also
be taken into account if alternative treatments are available.
Vaptans are effective in correcting hyponatremia with high
levels of serum vasopressin and high urine osmolality values.
They can be used as initial treatment of hyponatremias with
urine osmolality that is persistently elevated but should never be
used simultaneously with hypertonic saline. The risk of over-
correction of [Na]s is very high in this case. Vaptans are contra-
indicated in hyponatremias with urine osmolality that is high
initially but is lowered after saline infusion and they are inef-
fective in hyponatremia with dilute urine. Desmopressin infu-
sion is ineffective for hyponatremias with persistently high
urine osmolality but offers the best option for preventing over-
correction of severe hyponatremia with urine that is initially
FIGURE 2. Initial management of severe hyponatremia.
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concentrated but responds to saline infusion with dilution. Des-
mopressin infusion is also indicated for most categories of
severe hyponatremia with dilute urine. Characterization of the
volume status is critical for the choice of treatment. Hypovole-
mia in hyponatremic patients may not be detectable by clinical
means. Use of desmopressin as initial treatment of hyponatre-
mia if there are doubts about the presence of hypovolemia is
prudent. Monitoring of [Na]s, urine ﬂow rate and, in selected
cases, urine sodium and potassium concentration is critical dur-
ing treatment of severe hyponatremia regardless of the method
of treatment. Monitoring should be intensiﬁed if vaptans are
used. The use of vaptans or desmopressin in certain types of
hyponatremia will require further studies.
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